Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
CD20 expression + PAX5 expression + BCL2 expression
i
Other names:
CD20, MS4A1, Membrane Spanning 4-Domains A1, Membrane-Spanning 4-Domains, Subfamily A, Member 1, Leukocyte Surface Antigen Leu-16, B-Lymphocyte Antigen CD20, CD20 Antigen, Membrane-Spanning 4-Domains Subfamily A Member 1, B-Lymphocyte Cell-Surface Antigen B1, B-Lymphocyte Surface Antigen B1, CD20 Receptor, LEU-16, CVID5, MS4A2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
596
;
494216
;
5079
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
MYC rearrangement + BCL2 rearrangement (22)
BCL2 mutation (6)
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement (6)
BCL2 G101V (4)
BCL2 rearrangement (3)
MYC translocation + BCL2 translocation (3)
BCL2 D103Y (2)
PAX5 mutation (2)
BCL2 F104I (1)
BCL2 G101V + SF3B1 mutation (1)
BCL2 N103E (1)
BCL2 N103Y (1)
BCL2 N107_N110dup (1)
BCL2 V156N (1)
EZH2 mutation + BCL2 translocation (1)
MYC translocation + BCL6 translocation + BCL2 translocation (1)
TP53 mutation + BCL2 rearrangement (1)
BCL2 translocation (0)
MYC rearrangement + BCL2 rearrangement+ BCL6 rearrangement (0)
MYC rearrangement + BCL2 rearrangement (22)
BCL2 mutation (6)
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement (6)
BCL2 G101V (4)
BCL2 rearrangement (3)
MYC translocation + BCL2 translocation (3)
BCL2 D103Y (2)
PAX5 mutation (2)
BCL2 F104I (1)
BCL2 G101V + SF3B1 mutation (1)
BCL2 N103E (1)
BCL2 N103Y (1)
BCL2 N107_N110dup (1)
BCL2 V156N (1)
EZH2 mutation + BCL2 translocation (1)
MYC translocation + BCL6 translocation + BCL2 translocation (1)
TP53 mutation + BCL2 rearrangement (1)
BCL2 translocation (0)
MYC rearrangement + BCL2 rearrangement+ BCL6 rearrangement (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
CD20 expression + PAX5 expression + BCL2 expression
Marginal Zone Lymphoma
CD20 expression + PAX5 expression + BCL2 expression
Marginal Zone Lymphoma
rituximab
Sensitive: C4 – Case Studies
rituximab
Sensitive
:
C4
rituximab
Sensitive: C4 – Case Studies
rituximab
Sensitive
:
C4
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.